BACKGROUND:Fatigue among patients with cancer is prevalent, disabling, and treatable.
While fatigue management guidelines have been in place for a decade, their use remains unclear.
METHODS:We surveyed 160 patients with stage IV lung (40), breast (40), colon (40), and prostate (40) cancer who reported moderate to severe fatigue (i.e., >5 of 10 on an 11-point numerical rating scale). Participants were queried about receipt of treatments in fatigue management domains emphasized in the National Comprehensive Cancer Network guidelines: general management strategies, activity enhancement, psychosocial strategies, and pharmaceuticals.
RESULTS:The cohort was half male, had a mean age of 67, and reported an average fatigue rating of 6.4. Participants reported treatment or receipt of specific guidance in the fatigue management domains as follows: general management strategies 16.8 %, activity enhancement 11.9 %, psychosocial strategies 9.9 %, and pharmaceuticals 37.3 %. Fatigue >7 of 10 increased the likelihood of instruction in activity enhancement but no other domain.
CONCLUSION: The low rates of guideline-congruent treatment reported here are concerning, particularly as better validated behavioral treatments were the least prescribed.
Written by:
Cheville AL, Shen T, Chang M, Basford JR. Are you the author?
Department of Physical Medicine and Rehabilitation, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Reference: Support Care Cancer. 2012 Aug 23. Epub ahead of print.
doi: 10.1007/s00520-012-1515-7
PubMed Abstract
PMID: 22915355
UroToday.com Prostate Cancer Section
